Serine protease inhibitors act as modulators of serine proteases, playing important roles in protecting animal toxin peptides from degradation. However, all known serine protease inhibitors discovered thus far from animal venom belong to the Kunitz-type subfamily, and whether there are other novel types of protease inhibitors in animal venom remains unclear.
Here, by screening scorpion venom gland cDNA libraries, we identified the first Ascaris-type animal toxin family, which contains four members: Scorpiops jendeki Ascaris-type protease inhibitor (SjAPI), Scorpiops jendeki Ascaris-type protease inhibitor 2 (SjAPI-2), Chaerilus tricostatus Ascaris-type protease inhibitor (CtAPI), and Buthus martensii Ascaris-type protease inhibitor (BmAPI). The detailed characterization of Ascaris-type peptide SjAPI from the venom gland of scorpion Scorpiops jendeki was carried out. The mature peptide of SjAPI contains 64 residues and possesses a classical Ascaris-type cysteine framework reticulated by five disulfide bridges, different from all known protease inhibitors from venomous animals. Enzyme and inhibitor reaction kinetics experiments showed that recombinant SjAPI was a dual function peptide with α-chymotrypsin- and elastase-inhibiting properties. Recombinant SjAPI inhibited α-chymotrypsin with a Ki of 97.1 nM and elastase with a Ki of 3.7 μM, respectively. Bioinformatics analyses and chimera experiments indicated that SjAPI contained the unique short side chain functional residues “AAV” and might be a useful template to produce new serine protease inhibitors.
To our knowledge, SjAPI is the first functionally characterized animal toxin peptide with an Ascaris-type fold. The structural and functional diversity of animal toxins with protease-inhibiting properties suggested that bioactive peptides from animal venom glands might be a new source of protease inhibitors, which will accelerate the development of diagnostic and therapeutic agents for human diseases that target diverse proteases.
Citation: Chen Z, Wang B, Hu J, Yang W, Cao Z, Zhuo R, et al. (2013) SjAPI, the First Functionally Characterized Ascaris-Type Protease Inhibitor from Animal Venoms. PLoS ONE 8(3): e57529. https://doi.org/10.1371/journal.pone.0057529
Editor: Paulo Lee Ho, Instituto Butantan, Brazil
Received: November 10, 2012; Accepted: January 22, 2013; Published: March 22, 2013
Copyright: © 2013 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Basic Research Program of China (2010CB529800 and 2009CB918600), National High Technology Research and Development Program of China (2012AA020304), the China Postdoctoral Science Foundation (2012M511659), and the National Natural Sciences Foundation of China (30530140, 31071942, 30900265, 30973636, and 90813017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Serine protease inhibitors are of broad interest and can act as tools and modulators for serine proteases . Diverse interactions between these inhibitors and proteases play key roles in a variety of physiological functions, such as blood coagulation, fibrinolysis, apoptosis, development, inflammation, and complement activation in humans –. Serine protease inhibitors exist widely, not only in the bodies of various animals, but also in the secretions of parasites, hematophagous invertebrates, amphibian skins, and the venom glands of poisonous animals , –. Previous studies have indicated that protease inhibitors from venom glands might protect toxin peptides from degradation by various proteases and play important roles for venomous animal survival –. All known serine protease inhibitors discovered thus far from animal venom belong to the Kunitz-type subfamily; whether there are other novel types of protease inhibitors in animal venom remains unclear .
Ascaris-type peptides constitute an important class of serine protease inhibitors. The Ascaris-type peptide was almost isolated from the parasitic worm Ascaris suum and has been implicated in the survival of the parasite within the host by the inhibition of exogenous host proteases –. Almost all Ascaris-type peptides have a common structural characteristic with four short β-strands arranged in two approximately perpendicular β-sheets and stabilized by five disulfide bridges: Cys I–Cys VII, Cys II–Cys VI, Cys III–Cys V, Cys IV–Cys X, and Cys VIII–Cys IX . The reactive site loop of Ascaris-type peptides is almost bounded by two disulfide bridges (Cys II–Cys VI and Cys III–Cys V) and is part of the long loop connecting strands β1 and β2, as seen in the Ascaris sp. trypsin inhibitor (ATI), Apis mellifera cathepsin G/chymotrypsin inhibitor-1 (AMCI-1), chymotrypsin/elastase inhibitor-1 (C/E-1), and Bombina bombina skin trypsin inhibitor (BSTI) –.
Here, by searching scorpion cDNA libraries, we reported four Ascaris-type peptide genes encoding SjAPI (Scorpiops jendeki Ascaris-type protease inhibitor), SjAPI-2 (Scorpiops jendeki Ascaris-type protease inhibitor 2), CtAPI (Chaerilus tricostatus Ascaris-type protease inhibitor), and BmAPI (Buthus martensii Ascaris-type protease inhibitor), and the detailed characterization of Ascaris-type peptide SjAPI from the venom gland of the scorpion Scorpiops jendeki. Enzyme and inhibitor reaction kinetics experiments showed that SjAPI was a dual-functional peptide with α-chymotrypsin- and elastase-inhibiting properties. To our knowledge, SjAPI is the first functionally characterized Ascaris-type toxin peptide derived from animal venom glands , .
Materials and Methods
Data screening for Ascaris-type animal toxins
The venom gland cDNA libraries of various scorpions from China were constructed as described previously , . Random colonies were selected for sequencing using the ABI 3730 automated sequencer. Open reading frames (ORFs) of the sequences were characterized using ORFfinder (http://www.ncbi.nlm.nih.gov/projects/gorf/). Signal peptides were removed using the SignalP 4.0 Server . All sequence alignments were performed using Clustal_X 1.83 software followed by manual adjustment. Sequences of Ascaris-type toxins were obtained by searching against our own cDNA libraries and the GenBank National Center for Biotechnology Information database (http://www.ncbi.nlm.nih.gov/) using the Basic Local Alignment Search Tool algorithm.
Construction of SjAPI expression vectors
Ascaris-type peptide SjAPI is a novel animal toxin with the unique characteristic of five disulfide bridges. Therefore, we attempted to use two expression vectors, pET-28a and pGEX-4T-1, to produce recombinant SjAPI in E. coli. The cDNA sequence of SjAPI from the Scorpiops jendeki venom gland cDNA library was used as the template for the generation of fragments using polymerase chain reaction (PCR). The PCR product of SjAPI was digested with BamHI and XhoI, and inserted into a modified pET-28a expression vector. After confirmation by sequencing, the plasmid was transformed into E. coli Rosetta (DE3) cells for expression. The expression vector pGEX-4T-SjAPI was constructed and transformed by a method similar to that described previously .
The QuikChange Site-Directed Mutagenesis Kit (Stratagene, U.S.A.) was used to produce mutants based on the wild-type plasmid pET-28a-SjAPI. All mutant plasmids were verified by DNA sequencing before expression.
Expression and purification of SjAPI and its mutants
The expression of GST-SjAPI and purification of the recombinant SjAPI peptide were carried out according to the method previously described . The expression and purification of the recombinant His-SjAPI peptide and its mutants was carried out as follows. Transformed cells containing the expression plasmid pET-28a-SjAPI were cultured at 37°C in LB medium with 30 μg/ml kanamycin. Protein synthesis was induced by the addition of 5–10 mM isopropyl β-D-thiogalactoside (IPTG) when the optical density at 600 nm reached 0.8–1.0. After 4 hours of continued growth at 37°C, cells from 1 L culture were harvested by centrifugation. The cell pellet was resuspended in phosphate-buffered saline (PBS) buffer and lysed by sonication on ice. The recombinant SjAPI was exclusively accumulated in inclusion bodies. The insoluble inclusion bodies were washed twice with washing buffer (1–2% Triton X-100 in PBS), and denatured in 2 ml denaturation solution (6 M guanidinium-HCl, 0.1 M Tris-HCl pH 8.0, 1 mM EDTA, 30 mM reduced glutathione). Then, rSjAPI was reactivated by 100-fold dilution in renaturation solutions with three different pHs (0.2 M ammonium acetate at pH 7.0, 8.5, or 9.5 containing 0.2 mM oxidized glutathione and 0.5 M arginine) at 16°C for 24 h. The soluble material was then desalted and enriched using centrifugal filter devices (Sartorius Stedim Biotech, Germany, cutoff value >5 kDa). The renatured peptide was finally purified by high-pressure liquid chromatography (HPLC) on a C18 column (10 mm ×250 mm, 5 μm; Elite-HPLC, China) with a constant flow rate of 5 ml/min. Peaks were detected at a wavelength of 230 nm. The fraction containing recombinant SjAPI was collected manually and lyophilized immediately. The molecular mass of purified rSjAPI was further analyzed by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS; Voyager-DESTR; Applied Biosystems).
The SjAPI mutants were produced using the same method, with the refolding pH at about 9.5. The secondary structures of SjAPI and its mutants were analyzed by circular dichroism (CD) spectroscopy. All samples were dissolved in water at a concentration of about 0.2 mg/ml. Spectra were recorded at 25°C over a wavelength range of 250 to 190 nm with a scan rate of 50 nm/min on a Jasco-810 spectropolarimeter. Each CD spectrum was obtained as an average of three scans after subtracting the blank spectrum of water.
Structure modeling and molecular dynamics (MD) simulation
MD simulation was used to predict the putative active site of SjAPI as follows. The atomic structure of SjAPI was modeled using an Ascaris-type peptide AMCI-1 (PDB code 1CCV) as the template as previously described . The structure of elastase was extracted from the C/E-1 and elastase complex (PDB code: 1EAI) . Then an SjAPI-elastase complex was obtained by the distance restraint homologous modeling method on the basis of the C/E-1-elastase complex and subjected to MD simulation in explicit solvent to test its stability . The structure of the SjAPI-α-chymotrypsin complex was obtained using a similar method on the basis of the guamerin-α-chymotrypsin complex (PDB code: 3BG4) .
Serine protease inhibitory activity assay
The inhibitory activities of SjAPI and its mutants were tested by methods similar to those described previously , . Trypsin (bovine pancreatic trypsin; EC 22.214.171.124), chymotrypsin (bovine pancreatic α-chymotrypsin; EC 126.96.36.199), elastase (porcine pancreatic elastase; EC 188.8.131.52), and their respective chromogenic substrates Na-benzoyl-L-arginine 4-nitroanilide hydrochloride N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, and N-succinyl-Ala-Ala-Ala-p-nitroanilide, were purchased from Sigma (U.S.A). The initial rate of every reaction was monitored continuously at 405 nm for 5 min at 25°C. The inhibitory constant (Ki) of the protease/inhibitor complex was determined by Lineweaver-Burk plots followed by further slope replotting to yield a Ki value.
Scorpion venom gland cDNA libraries, a new source of Ascaris-type peptides
From the sequenced ESTs of scorpion cDNA libraries, we identified four genes encoding the Ascaris-type peptides SjAPI, SjAPI-2, CtAPI, and BmAPI (Fig. 1A). Multiple sequence alignments showed that the four Ascaris-type peptides from scorpion venom share homology with typical Ascaris-type venom peptides from other animals, such as ATI from Ascaris lumbricoides var. suum , AMCI-1 from Apis mellifera , BSTI from the skin secretions of Bombina bombina , C/E-1 from Ascaris suum , and NAP5 from Ancylostoma caninum . Phylogenetic tree analysis showed that among the representative Ascaris-type peptides, four Ascaris-type peptides from scorpion venom (SjAPI, SjAPI-2, CtAPI, BmAPI) and one Ascaris-type peptide from the secretion of frog skins (BSTI) were assigned to a single group (Fig. 1B), suggesting similarities between peptide toxins from animal venom glands and secreted peptides from amphibious skins .
(A) Amino acid sequence alignments of SjAPI, SjAPI-2, CtAPI, and BmAPI with known representative Ascaris-type peptides. The sequence identities of different Ascaris-type peptides to SjAPI were shown on the right side. (B) A minimum evolution (ME) tree of representative Ascaris-type proteins based on multiple sequence alignment.
Sequence analysis of SjAPI, a member of the Ascaris-type toxin family
As a representative member of the Ascaris-type toxin family, SjAPI has a precursor nucleotide sequence of 415 nucleotides (nt) including three parts: the 5′ untranslated region (UTR), the ORF, and the 3′ UTR. The 5′ UTR is only 20 nt long and the 3′ UTR is 110 nt long. The ORF region of 285 nt encodes a precursor polypeptide of 94 amino acid residues, including a signal peptide of 24 residues, a short propeptide of 6 residues, and a mature peptide of 64 residues, with the unique feature of 10 cysteine residues (Fig. 2). The mature SjAPI peptide possesses the classical Ascaris-type cysteine framework reticulated by five disulfide bridges, which is conserved in classical Ascaris-type peptides such as ATI and AMCI-1 and is distinct from all known protease inhibitors from venomous animals , , .
Cloning, expression, and refolding of SjAPI
Two expression systems were attempted to obtain recombinant SjAPI. Small-scale expression tests showed that both GST-SjAPI and His-SjAPI were expressed in inclusion bodies, so we chose His-SjAPI to produce large quantities of recombinant SjAPI peptide. Refolding of Ascaris-type peptides was a challenge due to their 10 cysteine residues , and we chose to refold SjAPI at three different pH levels in the present of 0.5 M arginine (Fig. 3A–C). Soluble and functional SjAPI was successfully obtained upon refolding at pH 9.5. Recombinant SjAPI (rSjAPI) was separated by reverse phase (RP)-HPLC and the peak eluting at 19.3 min, corresponding to rSjAPI, was collected manually. MALDI-TOF-MS showed a doubly charged ion at m/z 4506.14 and a singly charged ion at m/z 9012.89. Both MALDI-TOF-MS and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analyses showed that rSjAPI was expressed and purified successfully (Fig. 3D). Subsequently, rSjAPI was quantified by the BCA Protein Assay kit (Thermo Fisher Scientific) and stored at −20°C after freeze-drying.
(A) Purification of rSjAPI refolded at pH 7.0 by RP-HPLC. (B) Purification of rSjAPI refolded at pH 8.5 by RP-HPLC. (C) Purification of rSjAPI refolded at pH 9.5 by RP-HPLC. (D) Tricine-SDS-PAGE and MALDI-TOF-MS mass spectrum analysis of rSjAPI purification. M, marker; lane 1, total cell-free extract of E. coli carrying pGEX-6p-1-ImKTx1 uninduced; lane2, total cell-free extract of E. coli carrying pGEX-6p-1-ImKTx1 induced with IPTG; lane 3, purified rSjAPI peptide using centrifugal filter; 4, purified rSjAPI by RP-HPLC. MALDI-TOF-MS showed a singly charged ion at m/z 9012.89.
Pharmacological activities of rSjAPI on serine proteases
After obtaining the rSjAPI peptide, we tested its inhibitory effects on three representative serine proteases, trypsin at 500 nM, α-chymotrypsin at 100 nM and elastase at 150 nM. The results showed that rSjAPI was a dual-functional peptide with α-chymotrypsin- and elastase-inhibiting properties, but had no effect on trypsin (Fig. 4). The inhibitory constant (Ki) was further determined by Lineweaver-Burk plots and subsequent slope replotting. rSjAPI inhibited α-chymotrypsin and elastase with Ki values of 97.1±6.5 nM and 3.7±0.4 μM, respectively (Fig. 5 and Table 1).
(A) The concentration dependence of inhibitions on trypsin was shown with different concentrations of rSjAPI. (B) The concentration dependence of inhibitions on α-chymotrypsin was shown with different concentrations of rSjAPI. (C) The concentration dependence of inhibition on elastase was shown with different concentrations of rSjAPI. Trypsin (final concentration 500 nM), α-chymotrypsin (final concentration 100 nM), elastase (final concentration 150 nM) were each incubated with various concentrations of rSjAPI (0–2500 nM) for 30 min. All data represent the mean ± standard error of at least three experiments.
(A) Lineweaver-Burk plots for the determination of Km/Vmax values of α-chymotrypsin activity on a synthetic chromogenic substrate in the absence or presence of 60 nM, 75 nM, and 125 nM rSjAPI, respectively. Secondary plot: the slopes (Km/Vmax) of the primary Lineweaver-Burk graphs were plotted against the inhibitor concentration. The inhibitory constant (Ki) is determined from the intercept point on the x-axis. (B) Lineweaver-Burk plots and secondary plots show the inhibition of elastase by rSjAPI in the absence or presence of 625 nM, 1250 nM, and 2500 nM rSjAPI, respectively. Ki values were showed as the mean ± standard error at least three experiments.
Functional site analysis and chimeras design of SjAPI
Structure-function relationship research has shown that the binding loop of Ascaris-type peptides is located in a conserved region between cysteine V and VI . In SjAPI, this region corresponds to the sequence “AAV,” in which Ala34 is the P1 site, Ala33 is the P2 site, and Val35 is P1' site (Fig. 1A and Fig. S1). MD simulation was employed to probe inhibitor-protease interactions in detail. The results confirmed that the inhibitory activity of SjAPI was more potent for chymotrypsin than for elastase (Fig. 6). Beside the hydrophobic interactions, the amide group of Ala34 in SjAPI and the hydroxyl group of Ser189 in chymotrypsin formed hydrogen bond pair and contributed to the interaction between SjAPI and chymotrypsin (Fig. 6B and C). The carboxyl group of Ala34 in SjAPI formed hydrogen bond pairs with the groups of Ser185 and Gly183 in elastase, and the carboxyl group of Ala33 in SjAPI formed hydrogen bond pair with the group of Gln185 in elastase, and all these bond pairs contributed to the interaction between SjAPI and elastase (Fig. 6E and F).
(B) Ala34, the P1 site of SjAPI, fits into the pocket of chymotrypsin. (C) Residues of chymotrypsin interacting with Ala33, Ala34 and Val35 residues, the P1′, P1 and P2 sites of SjAPI. (D) The SjAPI-elastase complex predicted by MD simulation. (E) Ala34, the P1 site of SjAPI, fits into the pocket of elastase. (F) Residues of elastase interacting with Ala33, Ala34 and Val35 residues, the P1′, P1 and P2 sites of SjAPI.
Considering that the “AAV” sequence is made up of three short side chain residues, we designed six chimeras to further evaluate the functional sites P2, P1, and P1' of SjAPI instead of using conventional alanine-scanning-mutagenesis . The chimeras included SjAPI-M1 from the Ascaris-type peptide AMCI-1 , SjAPI-M2 from the Ascaris-type peptide ATI , SjAPI-M3 from the Ascaris-type peptide C/E-1 , SjAPI-M4 from the Kazal-type peptide OMTKY3 , SjAPI-M5 from the potato I family peptide CMTI-V , and SjAPI-M6 from the potato I family peptide CI-2  (Fig. 7A). CD spectroscopy analysis showed that the six chimeras had secondary structures similar to that of SjAPI (Fig. S2). Enzyme and inhibitor reaction kinetics experiments showed that all six chimeras were effective serine protease inhibitors, but exhibited different activities corresponding to their different P2, P1, and P1' site residues (Fig. S3).
(A) Amino acid sequence alignments of six chimeras and SjAPI. SjAPI-M1 was from the Ascaris-type peptide AMCI-1, SjAPI-M2 was from the Ascaris-type peptide ATI, SjAPI-M3 was from the Ascaris-type peptide C/E-1, SjAPI-M4 was from the Kazal-type peptide OMTKY3, SjAPI-M5 was from the potato I family peptide CMTI-V, and SjAPI-M6 was from the potato I family peptide CI-2. (B) Comparison of the serine protease inhibitory activity profiles of six chimeras with those of their templates and SjAPI.
As a unique dual serine protease inhibitor with three short side chain residues (“AAV”) at the P1, P2, and P1' sites, SjAPI was a good molecular scaffold to study the relationship between P1, P2, P1' sites and other potent sites in serine protease inhibitors. Our results showed that the inhibitory activity profiles of the six chimeras were not always consistent with their templates, although the P1, P2, and P1' sites were the same as in their templates (Fig. 7B). For example, the chimera SjAPI-M4 and the wild-type peptide OMTJY3 have the same P2, P1, and P1' sites, “TLE.” However, enzyme and inhibitor reaction kinetics experiments showed that SjAPI-M4 inhibits trypsin and α-chymotrypsin, but has no effect on elastase, in contrast to the wild-type peptide OMTJY3, which shows α-chymotrypsin and elastase inhibitory properties. The chimera SjAPI-M2 and the wild-type peptide ATI have the same P2, P1, and P1' sites “TMQ,” but SjAPI-M2 can inhibit α-chymotrypsin, whereas ATI has no effect on α-chymotrypsin. On the other hand, SjAPI-M1, SjAPI-M3, SjAPI-M5 and SjAPI-M6 retained inhibitory activity profiles that were partly similar to that of SjAPI, although their P2, P1, and P1' sites were completely different. SjAPI-M2 and SjAPI-M4 retained the α-chymotrypsin inhibitory activity and lost the elastase inhibitory activity of SjAPI, but the acquired new trypsin inhibitory activity. These results indicate that residues other than those at the P2, P1, and P1' sites might also play important roles in inhibitor-protease interactions and should be considered in protease inhibitor engineering to improve their activities and specificities , .
Over 400 million years, scorpion evolved a combinatorial library of bioactive components including peptides, proteins, and other biologically active substances  In this work, by screening scorpion venom gland cDNA libraries, we identified the first Ascaris-type animal toxin family, and characterized a dual-function Ascaris-type peptide SjAPI with α-chymotrypsin- and elastase-inhibitory activities.
Overall, our present work has provided the first insight into the following unique structural and functional features of the Ascaris-type animal toxin family: (1) Molecular diversity of Ascaris-type toxins: In this study, we identified four Ascaris-type peptides from scorpion venom glands, and all four Ascaris-type peptides share low homology with known Ascaris-type peptides from other phyla. Given a large number of unidentified toxin peptides from scorpion (over 90%) and other venomous animals, such as snake, spider, snail, and sea anemone , our results suggested that animal venom glands might be a new source of Ascaris-type peptides, and enriched the diversity of Ascaris-type peptides. (2) Structural diversity of venomous animal serine protease inhibitors: The three-dimensional (3-D) structure of SjAPI was built using AMCI-1 (PDB code 1CCV) as a template and showed a typical Ascaris-type scaffold (Fig. S1) . Prior to our work, all known serine protease inhibitors from venomous animals were Kunitz-type peptides, such as Hg1 from scorpion , OH-TCL and Bungaruskunin from snake , , APEKTx1 from sea anemone , and HWTX-XI from spider . Our study is the first to identify Ascaris-type peptide toxins with serine protease-inhibiting activities, thereby indicating the structural diversity of venomous animal serine protease inhibitors and also enriching diverse structural folds of scorpion toxins (Fig. S4). (3) Functional diversity of venomous animal serine protease inhibitors: Animal toxins must withstand a series of serine protease tests, and the diverse functions of different serine protease inhibitors might be needed in animal venoms , , . In our previous work, we identified scorpion derived protease inhibitor (SdPI), and it inhibits trypsin, but not α-chymotrypsin and elastase. Our prevent work showed that SjAPI inhibited α-chymotrypsin and elastase, but not trypsin, which indicated that the functional diversity and complementarity of serine protease inhibitors from animal venoms (Table 1). (4) Unique molecular template to produce diverse serine protease inhibitors: SjAPI contains the unique functional residues “AAV” at the P2, P1, and P1' sites. Our primary chimera designs indicated that all six chimeras were effective inhibitors of different serine proteases, but had different activities and specificities. Considering the difficulties in producing cysteine-enriched peptides and the functional expression of wild-type SjAPI and mutants in E. coli at about 2 mg/ml, our work provides an effective strategy for the design and production of various serine protease inhibitors using SjAPI as template , .
In summary, we identified the first Ascaris-type animal toxin family and characterized the unique Ascaris-type toxin SjAPI that has dual serine protease-inhibiting properties. To our knowledge, SjAPI is the first functionally characterized Ascaris-type toxin derived from animal venoms and represents a new structural fold that has been recruited into animal venoms .
Modeling of the 3-D structure of SjAPI. (A) The 3-D structure of SjAPI and the respective active residues were labeled. (B) The structure assessment for the modeled SjAPI displayed in the Ramachandran plot.
Circular dichroism spectrum analyses of rSjAPI and its chimeras. The six chimeras are SjAPI-M1, SjAPI-M2, SjAPI-M3, SjAPI-M4, SjAPI-M5, and SjAPI-M6. The measurement was carried out in the UV wavelength range of 250–190 nm at 25°C in water on a Jasco-810 spectropolarimeter at a concentration of about 0.2 mg/ml. All data represent the mean of at least three experiments.
Serine protease inhibitory activities of six chimeras. (A) The concentration dependence of inhibitions on trypsin was shown using different concentrations of SjAPI and six chimeras. (B) The concentration dependence of inhibitions on elastase was shown using different concentrations of SjAPI and six chimeras. (C) The concentration dependence of inhibitions on α-chymotrypsin was shown with different concentrations of SjAPI and six chimeras (0–2500 nM).
Diverse structural folds of scorpion toxins. (A) Representative scorpion toxin charybdotoxin with CSα/β fold. (B) Representative scorpion toxin κ-Hefutoxin 1 with CSα/α fold. (C) Representative scorpion toxin Maurocalcine with ICK fold. (D) Representative scorpion toxin U1-LITX-Lw1a with DDH fold. (E) Representative scorpion toxin SdPI with Kunitz-type fold. (F) Representative scorpion toxin SjAPI with Ascaris-type fold.
Read and approved the final manuscript: ZYC BW JH WSY ZJC YLW WXL RXZ. Conceived and designed the experiments: RXZ WXL YLW. Performed the experiments: ZYC BW WSY JH. Analyzed the data: ZYC WXL ZJC JH. Contributed reagents/materials/analysis tools: JH ZJC. Wrote the paper: ZYC YLW.
- 1. Van Gent D, Sharp P, Morgan K, Kalsheker N (2003) Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol 35: 1536–1547.
- 2. Zhao Y, Sun W, Zhang P, Chi H, Zhang MJ, et al. (2012) Nematode sperm maturation triggered by protease involves sperm-secreted serine protease inhibitor (Serpin). Proc Natl Acad Sci U S A 109: 1542–1547.
- 3. Jin X, Deng L, Li H, Zhang Z, He Q, et al. (2011) Identification and characterization of a serine protease inhibitor with two trypsin inhibitor-like domains from the human hookworm Ancylostoma duodenale. Parasitol Res 108: 287–295.
- 4. Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, et al. (2008) Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90: 284–295.
- 5. Davis AE 3rd, Lu F, Mejia P (2010) C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104: 886–893.
- 6. Fook JM, Macedo LL, Moura GE, Teixeira FM, Oliveira AS, et al. (2005) A serine proteinase inhibitor isolated from Tamarindus indica seeds and its effects on the release of human neutrophil elastase. Life Sci 76: 2881–2891.
- 7. Gomes CE, Barbosa AE, Macedo LL, Pitanga JC, Moura FT, et al. (2005) Effect of trypsin inhibitor from Crotalaria pallida seeds on Callosobruchus maculatus (cowpea weevil) and Ceratitis capitata (fruit fly). Plant Physiol Biochem 43: 1095–1102.
- 8. Minagawa S, Ishida M, Shimakura K, Nagashima Y, Shiomi K (1997) Isolation and amino acid sequences of two Kunitz-type protease inhibitors from the sea anemone Anthopleura aff. xanthogrammica. Comp Biochem Physiol B Biochem Mol Biol 118: 381–386.
- 9. Cheng YC, Yan FJ, Chang LS (2005) Taiwan cobra chymotrypsin inhibitor: cloning, functional expression and gene organization. Biochim Biophys Acta 1747: 213–220.
- 10. Lu J, Yang H, Yu H, Gao W, Lai R, et al. (2008) A novel serine protease inhibitor from Bungarus fasciatus venom. Peptides 29: 369–374.
- 11. Fry BG, Roelants K, Champagne DE, Scheib H, Tyndall JD, et al. (2009) The toxicogenomic multiverse: convergent recruitment of proteins into animal venoms. Annu Rev Genomics Hum Genet 10: 483–511.
- 12. Babin DR, Peanasky RJ, Goos SM (1984) The isoinhibitors of chymotrypsin/elastase from Ascaris lumbricoides: the primary structure. Arch Biochem Biophys 232: 143–161.
- 13. Peanasky RJ, Bentz Y, Homandberg GA, Minor ST, Babin DR (1984) The isoinhibitors of chymotrypsin/elastase from Ascaris lumbricoides: the reactive site. Arch Biochem Biophys 232: 135–142.
- 14. Peanasky RJ, Bentz Y, Paulson B, Graham DL, Babin DR (1984) The isoinhibitors of chymotrypsin/elastase from Ascaris lumbricoides: isolation by affinity chromatography and association with the enzymes. Arch Biochem Biophys 232: 127–134.
- 15. Gronenborn AM, Nilges M, Peanasky RJ, Clore GM (1990) Sequential resonance assignment and secondary structure determination of the Ascaris trypsin inhibitor, a member of a novel class of proteinase inhibitors. Biochemistry 29: 183–189.
- 16. Huang K, Strynadka NC, Bernard VD, Peanasky RJ, James MN (1994) The molecular structure of the complex of Ascaris chymotrypsin/elastase inhibitor with porcine elastase. Structure 2: 679–689.
- 17. Mignogna G, Pascarella S, Wechselberger C, Hinterleitner C, Mollay C, et al. (1996) BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes. Protein Sci 5: 357–362.
- 18. Cierpicki T, Bania J, Otlewski J (2000) NMR solution structure of Apis mellifera chymotrypsin/cathepsin G inhibitor-1 (AMCI-1): structural similarity with Ascaris protease inhibitors. Protein Sci 9: 976–984.
- 19. Chen ZY, Hu YT, Yang WS, He YW, Feng J, et al. (2012) Hg1, novel peptide inhibitor specific for Kv1.3 channels from first scorpion Kunitz-type potassium channel toxin family. J Biol Chem 287: 13813–13821.
- 20. Ma Y, He Y, Zhao R, Wu Y, Li W, et al. (2011) Extreme diversity of scorpion venom peptides and proteins revealed by transcriptomic analysis: Implication for proteome evolution of scorpion venom arsenal. J Proteomics 75(5): 1563–1576.
- 21. Zeng XC, Li WX, Zhu SY, Peng F, Jiang DH, et al. (2000) Cloning and characterization of the cDNA sequences of two venom peptides from Chinese scorpion Buthus martensii Karsch (BmK). Toxicon 38: 893–899.
- 22. Bendtsen JD, Nielsen H, von Heijne G, Brunak S (2004) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783–795.
- 23. Han S, Yi H, Yin SJ, Chen ZY, Liu H, et al. (2008) Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem 283: 19058–19065.
- 24. Wu Y, Cao Z, Yi H, Jiang D, Mao X, et al. (2004) Simulation of the interaction between ScyTx and small conductance calcium-activated potassium channel by docking and MM-PBSA. Biophys J 87: 105–112.
- 25. Zhao R, Dai H, Qiu S, Li T, He Y, et al. (2011) SdPI, the first functionally characterized Kunitz-type trypsin inhibitor from scorpion venom. PLoS One 6: e27548.
- 26. Kim H, Chu TT, Kim DY, Kim DR, Nguyen CM, et al. (2008) The crystal structure of guamerin in complex with chymotrypsin and the development of an elastase-specific inhibitor. J Mol Biol 376: 184–192.
- 27. Grasberger BL, Clore GM, Gronenborn AM (1994) High-resolution structure of Ascaris trypsin inhibitor in solution: direct evidence for a pH-induced conformational transition in the reactive site. Structure 2: 669–678.
- 28. Rios-Steiner JL, Murakami MT, Tulinsky A, Arni RK (2007) Active and exo-site inhibition of human factor Xa: structure of des-Gla factor Xa inhibited by NAP5, a potent nematode anticoagulant protein from Ancylostoma caninum. J Mol Biol 371: 774–786.
- 29. Lee HJ, Im H (2003) Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies. Protein Expr Purif 31: 99–107.
- 30. Otlewski J, Jaskolski M, Buczek O, Cierpicki T, Czapinska H, et al. (2001) Structure-function relationship of serine protease-protein inhibitor interaction. Acta Biochim Pol 48: 419–428.
- 31. Hoogstraten CG, Choe S, Westler WM, Markley JL (1995) Comparison of the accuracy of protein solution structures derived from conventional and network-edited NOESY data. Protein Sci 4: 2289–2299.
- 32. Liu J, Prakash O, Cai M, Gong Y, Huang Y, et al. (1996) Solution structure and backbone dynamics of recombinant Cucurbita maxima trypsin inhibitor-V determined by NMR spectroscopy. Biochemistry 35: 1516–1524.
- 33. McPhalen CA, James MN (1987) Crystal and molecular structure of the serine proteinase inhibitor CI-2 from barley seeds. Biochemistry 26: 261–269.
- 34. Salameh MA, Soares AS, Hockla A, Radisky DC, Radisky ES (2011) The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity. Biochem J 440: 95–105.
- 35. Berg DT, Gerlitz B, Shang J, Smith T, Santa P, et al. (2003) Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A 100: 4423–4428.
- 36. Froy O, Sagiv T, Poreh M, Urbach D, Zilberberg N, et al. (1999) Dynamic diversification from a putative common ancestor of scorpion toxins affecting sodium, potassium, and chloride channels. J Mol Evol 48: 187–196.
- 37. He QY, He QZ, Deng XC, Yao L, Meng E, et al. (2008) ATDB: a uni-database platform for animal toxins. Nucleic Acids Res 36: D293–297.
- 38. He YY, Liu SB, Lee WH, Qian JQ, Zhang Y (2008) Isolation, expression and characterization of a novel dual serine protease inhibitor, OH-TCI, from king cobra venom. Peptides 29: 1692–1699.
- 39. Peigneur S, Billen B, Derua R, Waelkens E, Debaveye S, et al. (2011) A bifunctional sea anemone peptide with Kunitz type protease and potassium channel inhibiting properties. Biochem Pharmacol 82: 81–90.
- 40. Yuan CH, He QY, Peng K, Diao JB, Jiang LP, et al. (2008) Discovery of a distinct superfamily of Kunitz-type toxin (KTT) from tarantulas. PLoS One 3: e3414.
- 41. Lee J, Natarajan M, Nashine VC, Socolich M, Vo T, et al. (2008) Surface sites for engineering allosteric control in proteins. Science 322: 438–442.